<DOC>
	<DOC>NCT01487629</DOC>
	<brief_summary>The purpose of this study is to compare the morphological and visual acuity outcomes associated with 1.5 mg bevacizumab versus 0.5 ranibizumab intravitreal injections for treatment of diabetic macular edema.</brief_summary>
	<brief_title>Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Centerinvolving Diabetic macular edema unresponsive to LASER therapy performed at least 3 moths prior to inclusion; Best corrected visual acuity equal or worse than 20/40 and better than 20/800; Central subfield macular thickness greater than 300 Âµm Aphakia Highrisk proliferative diabetic retinopathy Previous treatment for DME in the past three months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>